5-MeO-MiPT

Current federal law lists 5-MeO-MiPT in Schedule I.

5-MeO-MiPT is expressly scheduled as a Schedule 1 dangerous drug in Queensland, and unlawful possession is a crime under the current Queensland Act. Federally, the current Criminal Code Regulations list the closely corresponding 5-MeO-DiPT as a border controlled drug and the Criminal Code treats qualifying analogues of listed border drugs as border controlled, with importing or exporting a border controlled drug criminalized by section 307.3. Customs Schedule 4 and the current Poisons Standard Schedule 9 list related named tryptamines but no exact 5-MeO-MiPT entry; Customs uses a narrower chemically derived-and-regenerable derivative definition, while the Poisons Standard requires a fact-specific balanced derivative assessment. The express Queensland classification does not establish an identical possession schedule in every State or Territory; the federal analogue pathway and any state or territory analogue rules remain dependent on the statutory elements and substance characterization.

5-MeO-MiPT is not named individually in Austrian federal law and does not appear in Anlage I of the Neue-Psychoaktive-Substanzen-Verordnung (NPSV), but it falls within the tryptamine class of NPSV Anlage II point 6, which covers tryptamine and any compound derivable from that base structure, including one bearing as substituents the chemical structures enumerated in NPSV § 1(2), among them alkyls, alkoxides and ethers; 5-MeO-MiPT has a tryptamine skeleton carrying N-methyl and N-isopropyl alkyl groups on the side-chain nitrogen and a 5-methoxy group on the indole ring. Under the Anlage II text in force since 19 April 2024, § 4(1) of the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) punishes producing, importing, exporting, supplying or procuring a covered new psychoactive substance with imprisonment of up to two years, where the person acts with intent to obtain an advantage and with intent that another person use the substance to achieve a psychoactive effect in the human body, and § 4(2) raises the penalty to one to ten years where the offence causes a person's death or serious bodily injuries to a larger number of people. The NPSG sets out no separate offence of simple possession, but § 5(1) makes confiscation mandatory even where no particular person can be prosecuted or convicted under § 4, unless the person entitled to dispose of the substance credibly establishes a lawful purpose of use and guarantees that it will not be used for a psychoactive effect in the human body. The NPSG governs because its § 2 excludes substances and preparations subject to the Suchtmittelgesetz, and 5-MeO-MiPT has no entry in the Suchtgiftverordnung or the Psychotropenverordnung.

5-MeO-MiPT is expressly and nominally scheduled in the current Lista F2, not merely captured by an analogue or generic tryptamine provision. Its salts and isomers are also controlled under F2 Adendo 1.1. The narrow authorized medical/scientific/research exception in Portaria Art. 4 and the legal or regulatory authorization/licensing provisions do not make ordinary possession, supply, production, import, export or use lawful.

5-MeO-MiPT is expressly listed in China's operative national non-pharmaceutical narcotic and psychotropic schedule. The current regulation permits non-pharmaceutical controlled substances only for authorized experimental research and prohibits ordinary production, commercial operation, use, storage and transport. The schedule also covers possible salts and stereoisomers unless otherwise specified. Article 2 of the regulation provides that import and export are governed by applicable separate laws.

5-MeO-MiPT is not named individually in German law and does not appear in Anlagen I to III of the Betäubungsmittelgesetz, but it falls within the tryptamine substance group of Anlage 1 Nummer 5.1 of the Neue-psychoaktive-Stoffe-Gesetz (NpSG), which covers any compound derivable from the indol-3-alkylamine base structure with a molecular mass of at most 500 u and bearing the listed substituents, together with all charged forms, stereoisomers, salts, and isotope-substituted forms, while tryptamine itself, the naturally occurring neurotransmitters serotonin and melatonin, and their active metabolites are expressly excluded from the group. Under the Anlage 1 text in force since 2 December 2025, NpSG § 3(1) no. 1 prohibits trading in the substance, placing it on the market, producing it, bringing it into, out of, or through Germany, acquiring it, possessing it, and administering it to another person, with exemptions for commercial, industrial, and scientific uses recognised according to the current state of science and technology and for federal and state authorities and the bodies they commission. Criminal liability under § 4(1) is directed at market-facing conduct, so trading, placing on the market, administering the substance to another person, and manufacturing it or bringing it into Germany for the purpose of placing it on the market carry imprisonment of up to three years or a fine; an attempt is punishable; the aggravated forms of § 4(3), which cover acting commercially or as a member of a gang, supplying, administering, or leaving the substance for immediate consumption to a person under 18 as a person over 21, endangering the health of a large number of people, and exposing another person to the danger of death or of serious injury to body or health, carry one to ten years, which § 4(4) reduces to three months to five years in less serious cases; negligent commission of the § 4(3) no. 1(b) and no. 2 variants in conjunction with § 4(1) no. 1 carries up to three years or a fine under § 4(5); and negligent conduct under § 4(1) no. 1 carries up to one year or a fine under § 4(6). Simple possession is prohibited but is not among the acts § 4(1) makes punishable, and the substance remains subject to seizure, safekeeping, and destruction under § 3(3) and to customs seizure under § 3(4); no quantity threshold and no personal-use amount applies to Anlage 1 substances.

5-MeO-MiPT is listed, by its systematic name N-isopropyl-5-methoxy-N-methyltryptamine and together with its salts, at item 56 of Article 1 of Ministry of Health, Labour and Welfare Ordinance No. 14 of 28 February 2007, which designates it a 指定薬物 (designated drug) under Article 2(15) of the Pharmaceuticals and Medical Devices Act with effect from 1 April 2007. Article 76-4 of that Act prohibits manufacturing, importing, selling, transferring, possessing, purchasing, or receiving the substance for any purpose other than 医療等の用途 (medical and other uses), and prohibits using it for any such other purpose; Article 76-4 itself counts the diagnosis, treatment, or prevention of disease among those uses, and Article 2 of the ordinance specifies the remainder as academic research and testing or inspection by national organs, local governments and their organs, universities and colleges of technology and inter-university research institutes, national and local incorporated administrative agencies, and the National Institute for Health Crisis Management, together with testing under Articles 69(4) and 69(6) of the Act, inspection under Article 76-6(1), testing under Article 76-8(1), and criminal forensic identification. Manufacturing, importing, selling, or transferring the substance as a business, or possessing it as a business by storing or displaying it for the purpose of sale or transfer, is punishable under Article 83-9 by imprisonment for up to five years or a fine of up to 5,000,000 yen, or both, while any other breach of Article 76-4 is punishable under Article 84 item 28 by imprisonment for up to three years or a fine of up to 3,000,000 yen, or both. Control follows the exact chemical name rather than a generic or analogue rule, and a designated drug is by definition not a narcotic under the Narcotics and Psychotropics Control Act, whose designation order lists 5-MeO-DALT and 5-MeO-DiPT but not 5-MeO-MiPT.

The exact name 5-MeO-MiPT is not printed in the current Annex 2 named-entry sequence. However, the operative List I generic tryptamine provision expressly covers beta-(indol-3-yl)ethanamine derivatives bearing benzene-ring and/or amino-group substituents, and the PubChem identity establishes that 5-MeO-MiPT has that core plus 5-methoxy, N-methyl and N-isopropyl substitution. List I is the prohibited category and § 5 bans ordinary cultivation, production, manufacture, import/export, distribution, advertising, transport, storage, transfer, acquisition, use and transit; quantity thresholds classify unlawful-circulation amounts and do not create a personal-use exception. The only identified authorization route is the narrow § 7 route for specified scientific, physical/chemical testing or training purposes.

As of 28 August 2026, 5-MeO-MiPT is classified as a drug in Turkey, and possession, production, supply and import are prohibited. The official Turkish Interior Ministry/General Directorate of Security 2013 Türkiye Uyuşturucu Raporu states that 60 new psychoactive substances were placed under Law No. 2313 by Council of Ministers Decision No. 2013/4827 (22 May 2013; published 25 June 2013 in Official Gazette No. 28688) and reproduces the Triptamin Grubu entry naming 5-MeO-MiPT and its full chemical name. The official 2025 Türkiye Uyuşturucu Raporu identifies Law No. 2313 and TCK Articles 188, 190 and 191 as the principal framework, describes the EWS process for placing NPS under Law No. 2313, reports generic classification in Turkey since 2015, and reports 1,078 NPS under the law through 31 July 2025. 5-MeO-MiPT is individually named in the 2013/4827 annex. The 2025 report's generic-classification discussion does not establish additional analogue coverage for this exact substance. Under the current Ministry of Justice TCK publication, unauthorized manufacture/import/export falls under Article 188(1) (20–30 years' imprisonment and 2,000–20,000 days' judicial fine); domestic sale, offer, giving, dispatch, transport, storage, purchase, acceptance or possession falls under Article 188(3) (at least 10 years' imprisonment and 1,000–20,000 days' judicial fine); personal-use purchase, acceptance, possession or use falls under Article 191(1) (2–5 years' imprisonment), with Article 191(2)–(3) postponement, supervision, possible treatment and testing rules. Article 188(4)(a)'s half-increase categories include synthetic-cannabinoid, synthetic-cathinone, synthetic-opioid and amphetamine derivatives; 5-MeO-MiPT is not attributed that enhancement merely because it is a tryptamine. This does not resolve product-specific licensing, quantity, evidentiary or charging questions.

5-MeO-MiPT is controlled in the United Kingdom under the Misuse of Drugs Act 1971 generic tryptamine provision; group or analogue treatment depends on the statutory scope.

5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine) is not independently named in the current Schedule 1 text, but its indole-ethylamine nucleus, N-methyl/N-isopropyl substitution, and 5-methoxy benzene substitution match the explicit Schedule 3 Part 7 DMT-analogue description. Section 2(1) makes a qualifying analogue a Class C controlled drug, so 5-MeO-MiPT is controlled under the analogue rule. The statutory Medicines Act and approved-product exclusions remain applicable if the substance were a qualifying excluded product.

5-MeO-MiPT is expressly named in Finland's current consumer-market-banned psychoactive-substance annex and is regulated under that designation rather than as a narcotic or an analogue. The current control prohibits manufacture, import, storage, offering for sale and transfer, with statutory research and industrial exceptions. Section 5(2) does not itself state the blanket possession/use prohibition applicable to narcotics under section 5(1). 5-MeO-MiPT does not appear by exact name or structural coverage in the current consolidated narcotics schedule decree 543/2008; distinct entries such as 5-MeO-DMT remain separate.

The consolidated Law No. 339/2005 annex names particular substances (including DMT, etriptamine, 5-MeO-DALT and other compounds) and applies its same-rules clause to isomers, ethers, esters and salts of listed substances; it does not create a generic tryptamine-derivative entry that expressly captures 5-MeO-MiPT. Because 5-MeO-MiPT is not named in the consolidated Table I, II or III text, the exact molecule is not expressly prohibited under a Law No. 339/2005 schedule or Table I. The residual Law No. 194/2011 framework applies to an otherwise unregulated product that is susceptible to psychoactive effects and can be used in place of a narcotic, psychotropic or nationally controlled substance: operations require authorization and are prohibited before authorization. Current penalty text must be distinguished from the 2014 republication: Law No. 58/2024 amended art. 16(1) to 3-10 years and disqualification from rights for knowing unauthorized operations; Law No. 172/2024 amended art. 16(2) to 1-5 years and disqualification where the person should or could have foreseen the psychoactive susceptibility, added 15-25 years and disqualification where death results, and made attempt punishable. These operation-based penalties do not establish that every act of possession or personal consumption of the exact unlisted molecule is a Law No. 339/2005 drug offence. The current legal treatment is therefore subject to the Law No. 194/2011 authorization framework, not an express prohibited scheduled-drug status; an authority's product-specific assessment under Law No. 194/2011 remains relevant.

5-MeO-MiPT is restricted under Swiss BetmVV-EDI Annex 6 Verzeichnis e.

The identified pure compound 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine) is not expressly listed under the CDSA: the complete current Schedules I-VI contain no exact entry and no generic tryptamine class rule, while Schedule III's 2C-phenethylamine class is structurally distinct from this indole tryptamine. The treatment of salts and analogues or derivatives depends on the applicable schedule wording.

5-MeO-MiPT appears in neither of the two grand-ducal regulations that designate substances under Article 7 of the loi modifiée du 19 février 1973: the annex to the Règlement grand-ducal modifié du 20 mars 1974 concernant certaines substances psychotropes, in its consolidated version applicable from 13 July 2026, runs from item 1 to item 66 and names no 5-MeO-MiPT, miprocin or 5-methoxy-N-methyl-N-isopropyltryptamine, and the annex to the Règlement grand-ducal modifié du 4 mars 1974 concernant certaines substances toxiques, consolidated to 29 September 2024, runs from item 1 to item 34 and names no tryptamine at all. The psychotropic annex lists tryptamines individually at item 1 (DET), item 3 (DMT), item 7 (psilocine), item 8 (psilocybine) and item 26 (etryptamine), while its group entries at item 10 (tetrahydrocannabinols and their isomers) and item 39 (synthetic and semi-synthetic cannabinoid receptor agonists) are cannabinoid classes, leaving the annex without any tryptamine class entry; Article 1er of that regulation extends control only to stereo-isomers of the annexed substances, to organisms naturally containing them and to biological material for reproducing such organisms, and 5-MeO-MiPT (C15H22N2O) is not a stereo-isomer of a listed substance, so no analogue or structural-class rule reaches it. It is likewise absent from the narcotics list under the Règlement grand-ducal modifié du 26 mars 1974, consolidated to 12 December 2025, whose control extends only to preparations, isomers, esters, ethers and salts of the substances it lists, and the most recent amendment of the psychotropic annex, the Règlement grand-ducal du 6 juillet 2026, added only 2-MMC, NEP and 4-BMC. The offences in Articles 7 and 8 of the loi modifiée du 19 février 1973 attach only to narcotics and to toxic, soporific or psychotropic substances designated by grand-ducal regulation, so personal use, transport, possession, acquisition and supply of 5-MeO-MiPT fall outside them.

Listed under 'Wykaz środków odurzających i substancji psychotropowych' (List of narcotic substances and psychotropic substances) in category I-P. Ownership, production, and sale are prohibited.